Qualigen shareholders approve all proposals; name change to AIxCrypto, Faraday Future becomes majority holder

AIxCrypto Holdings, Inc.

Stockholders approved private placement of 337,432 common shares and 39,943 Series B convertible preferred shares.
Faraday Future becomes majority owner with ~55% direct equity (incl. affiliates ~63%); will nominate majority of board.
Company rebrands to AIxCrypto Holdings, Inc., ticker changes to AIXC on Nov 20, 2025 from QLGN.
Company transitions from biotech to AI × Web3 platform, unveiling three-year roadmap at Nasdaq ceremony on Nov 20.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AIxCrypto Holdings, Inc.: Changed corporate name from Qualigen Therapeutics, Inc. to AIxCrypto Holdings, Inc (effective 2025-11-14).

Change: charter amendment
Effective: 2025-11-14

Exact text from the filing

On November 14, 2025, Qualigen Therapeutics, Inc. (the “Company”) filed with the State of Delaware a Certificate of Amendment to our Amended and Restated Certificate of Incorporation to change our corporate name from “Qualigen Therapeutics, Inc.” to “AIxCrypto Holdings, Inc.”

View on SEC.gov

241 governance changes filed in the last 30 days. Browse all governance changes →

AIxCrypto Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-023728

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.